Treatment for breast cancer patients during the special period of novel coronavirus pneumonia outbreak

Wenbin Zhou,Shui Wang,Hong Pan,Hui Xie,Jiaxin Zhang,Linlin Zhen,Chunhui Zhang,Qi Fang,Susheng Cao,Xiao Liu,Deyuan Fu,Xiaoqing Guan,Guoqin Jiang,Lingyun Xu,Enchao Shen,Qiang Geng,Xiudi Xiao,Jun Gu,Tongbo Yi,Xiaoan Liu
DOI: https://doi.org/10.21203/rs.3.rs-22428/v1
2020-01-01
Abstract:Abstract Purpose: The outbreak of novel coronavirus pneumonia occurred worldwide. 2019 novel coronavirus disease (COVID-19) can be transmitted from human to human, cause hospital infection, and seriously threatens surgical staffs and inpatients. The treatment of patients with breast cancer may be affected in this special period. Methods: From 24th January to 8th March 2020, patients diagnosed with breast cancer were enrolled from 16 hospitals in Jiangsu Province, and patients, who were candidates for surgery after neoadjuvant chemotherapy, were also enrolled. Patients from 24th January to 8th March 2019 were included as control with the same criteria. Results: In 2019, 520 patients were diagnosed with breast cancer in these 16 hospital; however, only 229 patients (decreased by 56%) were diagnosed with breast cancer in the same period of 2020. The clinical characteristics were similar between the two groups, and core biopsy was performed to more patients in 2020 than that in 2019 (4.1 days ±3.2 vs 3.2 days ±2.6, P < 0.001), and more patients underwent mastectomy and axillary lymph node dissection in 2020. After neoadjuvant chemotherapy, the mean interval between last time of neoadjuvant chemotherapy and surgery in 2020 was significantly longer than that in 2019 (29.2 days ±11.1 vs 17.7 days ±8.2, P < 0.001). After examinations to rule out COVID-19, no COVID-19 was found in any patient. Conclusions: In the special period of novel coronavirus pneumonia outbreak, the treatment of patients with breast cancer was delayed, but the treatment was safe after strict exclusions of COVID-19.
What problem does this paper attempt to address?